Tazanolast

Tazanolast

SCHEMBL28495

CCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.45
RAB9A P51151 2/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
CYP2C19 P33261 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
XDH P47989 2/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
PDE5A O76074 1/20 0.40
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE3B Q13370 1/20 0.40
PDE1C Q14123 1/20 0.40
PDE3A Q14432 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956335 0.82 HPGD (0.60) HPGDLMNASMN1; SMN2CYP2C19CYP1A2
Tazanolast SCHEMBL1651344 0.82 MAPT (0.61) HPGDRAB9ALMNACYP2C19NPC1
SCHEMBL950001 0.79 CYP3A4 (0.60) HPGDRAB9ALMNASMN1; SMN2CYP2C19
Acitazanolast SCHEMBL342549 0.79 GPR35 (0.54) HPGDRAB9ASMN1; SMN2NPC1TSHR
Acitazanolast SCHEMBL3116621 0.78 GPR35 (0.53) HPGDRAB9ASMN1; SMN2NPC1TSHR
SCHEMBL6694019 0.77 MAPT (0.59) HPGDRAB9ASMN1; SMN2NPC1CYP1A2
SCHEMBL22167182 0.77 MGLL (0.54) LMNAMAPTKMT2ACDK8
SCHEMBL9314587 0.76 MGLL (0.45) HPGDRAB9ASMN1; SMN2CYP2C19NPC1
SCHEMBL11647389 0.75 HPGD (0.76) HPGDRAB9ALMNASMN1; SMN2CYP2C19
SCHEMBL8947313 0.75 MAPT (0.44) HPGDRAB9ALMNASMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1093 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3400971-B1 ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE BIOTYX MEDICAL SHENZHEN CO LTD (CN) 2021-08-04 EP claimed
EP-3400969-B1 IMPLANTED DEVICE BIOTYX MEDICAL SHENZHEN CO LTD (CN) 2021-05-19 EP claimed
US-10946121-B2 Absorbable iron-based alloy implantable medical device BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) 2021-03-16 US claimed
EP-3400970-B1 ABSORBABLE IRON-BASED ALLOY MEDICAL DEVICE IMPLANT LIFETECH SCIENT SHENZHEN CO (CN) 2021-03-03 EP claimed
US-20200215237-A1 ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) 2020-07-09 US claimed
EP-2913062-B1 THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY JAPAN INNOVATIVE THERAPEUTICS INC (JP) 2019-05-08 EP claimed
US-20190022284-A1 Absorbable Iron-based Alloy Medical Device Implant LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD. (CN) 2019-01-24 US claimed
US-20190008996-A1 Implanted Device LIFETECH SCIENTIFIC (SHENZHEN) CO., LTD. (CN) 2019-01-10 US claimed
EP-3400969-A1 IMPLANTED DEVICE Lifetech Scientific (Shenzhen) Co., Ltd. (CN) 2018-11-14 EP claimed
EP-3400971-A1 ABSORBABLE IRON-BASED ALLOY IMPLANTABLE MEDICAL DEVICE Lifetech Scientific (Shenzhen) Co., Ltd. (CN) 2018-11-14 EP claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20040247628-A1 Kit for the preparation of a pharmaceutical composition PARI PHARMA GMBH (DE) 2004-12-09 US claimed
EP-1438019-A1 KIT FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION PARI GmbH Spezialisten für effektive Inhalation (DE) 2004-07-21 EP claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
WO-2003035030-A1 KIT FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION PARI GMBH (DE) 2003-05-01 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-5693337-A OIL IN WATER EMULSION CONTAINING DRUG, LECITHIN, CITRIC ACID, AND METHIONINE, PHENYLALANINE, SERINE, AND/OR HISTIDINE; SYNERGISTIC, STORAGE STABILITY WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) 1997-12-02 US claimed
EP-0700678-A1 Stable lipid emulsion Wakamoto Pharmaceutical Co., Ltd. (JP) 1996-03-13 EP claimed
EP-0481118-B1 A method for producing butyl 3'-(1H-tetrazol-5-yl) oxanilate WAKAMOTO PHARMA CO LTD (JP) 1995-08-02 EP claimed
US-4778816-A MIXING THE TETRAZOLE WITH DISPERSANT AND NONAQUEOUS SOLVENT; DESOLVENTIZING WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) 1988-10-18 US claimed